- Home
- PENG vs IRWD Comparison
PENG vs IRWD Comparison
Compare PENG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENG
- IRWD
- Stock Information
- Founded
- PENG 1988
- IRWD 1998
- Country
- PENG Cayman Islands
- IRWD United States
- Employees
- PENG N/A
- IRWD N/A
- Industry
- PENG Semiconductors
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- PENG Technology
- IRWD Health Care
- Exchange
- PENG Nasdaq
- IRWD Nasdaq
- Market Cap
- PENG 830.2M
- IRWD 716.9M
- IPO Year
- PENG 2017
- IRWD 2010
- Fundamental
- Price
- PENG $17.65
- IRWD $3.44
- Analyst Decision
- PENG Strong Buy
- IRWD Buy
- Analyst Count
- PENG 5
- IRWD 4
- Target Price
- PENG $23.60
- IRWD $12.00
- AVG Volume (30 Days)
- PENG 887.7K
- IRWD 1.6M
- Earning Date
- PENG 01-07-2025
- IRWD 11-07-2024
- Dividend Yield
- PENG N/A
- IRWD N/A
- EPS Growth
- PENG N/A
- IRWD N/A
- EPS
- PENG N/A
- IRWD N/A
- Revenue
- PENG $1,170,796,000.00
- IRWD $378,418,000.00
- Revenue This Year
- PENG N/A
- IRWD N/A
- Revenue Next Year
- PENG N/A
- IRWD N/A
- P/E Ratio
- PENG N/A
- IRWD N/A
- Revenue Growth
- PENG N/A
- IRWD N/A
- 52 Week Low
- PENG $14.87
- IRWD $3.26
- 52 Week High
- PENG $29.81
- IRWD $15.70
- Technical
- Relative Strength Index (RSI)
- PENG N/A
- IRWD 35.72
- Support Level
- PENG N/A
- IRWD $3.96
- Resistance Level
- PENG N/A
- IRWD $5.07
- Average True Range (ATR)
- PENG 0.00
- IRWD 0.34
- MACD
- PENG 0.00
- IRWD -0.12
- Stochastic Oscillator
- PENG 0.00
- IRWD 9.94
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.